Literature DB >> 12374759

Aggregate formation inhibits proteasomal degradation of polyglutamine proteins.

Lisette G G C Verhoef1, Kristina Lindsten, Maria G Masucci, Nico P Dantuma.   

Abstract

Insoluble protein aggregates are consistently found in neurodegenerative disorders caused by expanded polyglutamine [poly(Q)] repeats. The aggregates contain various components of the ubiquitin/proteasome system, suggesting an attempt of the cell to clear the aberrant substrate. To investigate the effect of expanded poly(Q) repeats on ubiquitin/proteasome-dependent proteolysis, we targeted these proteins for proteasomal degradation by the introduction of an N-end rule degradation signal. While soluble poly(Q) proteins were degraded, they resisted proteasomal degradation once present in the aggregates. Stabilization was also observed for proteins that are co-aggregated via interaction with the expanded poly(Q) domain. Introduction of a degradation signal in ataxin-1/Q92 reduced the incidence of nuclear inclusions and the cellular toxicity, conceivably by accelerating the clearance of the soluble substrate.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12374759     DOI: 10.1093/hmg/11.22.2689

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  100 in total

Review 1.  Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins.

Authors:  David C Butler; Julie A McLear; Anne Messer
Journal:  Prog Neurobiol       Date:  2011-11-18       Impact factor: 11.685

2.  Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases.

Authors:  Ruth A Bodner; Tiago Fleming Outeiro; Stephen Altmann; Michele M Maxwell; Stephanie H Cho; Bradley T Hyman; Pamela J McLean; Anne B Young; David E Housman; Aleksey G Kazantsev
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

Review 3.  Molecular pathogenesis of spinocerebellar ataxia type 6.

Authors:  Holly B Kordasiewicz; Christopher M Gomez
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

Review 4.  Aggresome formation and neurodegenerative diseases: therapeutic implications.

Authors:  J A Olzmann; L Li; L S Chin
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

5.  Selective accumulation of aggregation-prone proteasome substrates in response to proteotoxic stress.

Authors:  Florian A Salomons; Victoria Menéndez-Benito; Claudia Böttcher; Brett A McCray; J Paul Taylor; Nico P Dantuma
Journal:  Mol Cell Biol       Date:  2009-01-21       Impact factor: 4.272

6.  Accumulation of ubiquitin conjugates in a polyglutamine disease model occurs without global ubiquitin/proteasome system impairment.

Authors:  Christa J Maynard; Claudia Böttcher; Zaira Ortega; Ruben Smith; Bogdan I Florea; Miguel Díaz-Hernández; Patrik Brundin; Hermen S Overkleeft; Jia-Yi Li; Jose J Lucas; Nico P Dantuma
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-30       Impact factor: 11.205

Review 7.  Role of ubiquitin protein ligases in the pathogenesis of polyglutamine diseases.

Authors:  Priyanka Dikshit; Nihar Ranjan Jana
Journal:  Neurochem Res       Date:  2007-09-01       Impact factor: 3.996

8.  Single neuron ubiquitin-proteasome dynamics accompanying inclusion body formation in huntington disease.

Authors:  Siddhartha Mitra; Andrey S Tsvetkov; Steven Finkbeiner
Journal:  J Biol Chem       Date:  2008-12-10       Impact factor: 5.157

9.  p62 plays a protective role in the autophagic degradation of polyglutamine protein oligomers in polyglutamine disease model flies.

Authors:  Yuji Saitoh; Nobuhiro Fujikake; Yuma Okamoto; H Akiko Popiel; Yusuke Hatanaka; Morio Ueyama; Mari Suzuki; Sébastien Gaumer; Miho Murata; Keiji Wada; Yoshitaka Nagai
Journal:  J Biol Chem       Date:  2014-12-05       Impact factor: 5.157

Review 10.  The ubiquitin-proteasome pathway in Huntington's disease.

Authors:  Steven Finkbeiner; Siddhartha Mitra
Journal:  ScientificWorldJournal       Date:  2008-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.